Sinomenine Inhibits the Progression of Bladder Cancer Cells by Downregulating LncRNA-HEIH Expression

Xu, Haoming; Dong, Jiayan; Hou, Junhui; Gao, Rui

doi:10.1155/2021/4699529

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to the mechanism by which sinomenine inhibits cell proliferation, sinomenine and its derivatives can also activate the mitochondrial apoptosis pathway in bladder cancer and hepatocellular carcinoma by downregulating lncRNA-HEIH and miR-29 ( 12 , 20 ). In addition, sinomenine can induce apoptosis of pancreatic cancer cells by inducing G0/G1 cell cycle arrest and apoptosis of malignant glioma and liver cancer cells ( 35 ).…”

Section: Sinomenine Induces Tumor Cell Apoptosismentioning

confidence: 99%

“…LncRNA-HEIH is carcinogenic in various cancers. Xu et al found that lncRNA-HEIH was upregulated in bladder cancer cell lines (T24,5637, HT-1197, TCCSUP and SW 780) ( 12 ). However, sinomenine can downregulate the expression of lncRNA-HEIH, and knockdown of lncRNA-HEIH reversed the inhibition of proliferation in bladder cancer cells.…”

Section: Sinomenine Inhibits Tumor Cell Proliferationmentioning

confidence: 99%

See 1 more Smart Citation

The anti-tumor potential of sinomenine: a narrative review

Zhu,

Gao

2023

Transl Cancer Res

View full text Add to dashboard Cite

Background and Objective Currently, chemotherapy is the main treatment for most tumors. However, drug resistance and many adverse reactions associated with chemotherapy greatly limit its use. Therefore, an increasing number of researchers have shifted the research focus the anti-tumor activity of traditional Chinese medicine. The objective of this article is to review the anti-tumor mechanism of sinomenine and its derivatives to provide a reference for further study and clinical transformation. Methods In this study, we searched for relevant articles on the anti-tumor mechanism of Sinomenium using databases such as PubMed and Medline. Key Content and Findings Sinomenine is a monomer alkaloid component extracted from the rhizome of Sinomenium acuturn . A number of basic studies have proven that sinomenine and its derivatives show significant anti-tumor activity in breast cancer, lung cancer, liver cancer, stomach cancer, ovarian cancer, osteosarcoma and other tumors. They can induce apoptosis and autophagic death of tumor cells, inhibit proliferation, migration and invasion of tumor cells, increase the sensitivity of tumor cells to radiotherapy and chemotherapy, and reverse the drug resistance through various molecular mechanisms. In addition, sinomenine can effectively relieve osteolysis and bone pain in tumor patients. At present, anti-tumor research on sinomenine remains in the basic experimental stage. Conclusions Sinomenine and its derivatives are rich in substances with high anti-tumor potential. This analysis provides a review of the anti-tumor effects and mechanisms of sinomenine, with the hope of further exploring the medical value of sinomenine in anti-tumor treatments.

show abstract

Section: Sinomenine Induces Tumor Cell Apoptosismentioning

confidence: 99%

Section: Sinomenine Inhibits Tumor Cell Proliferationmentioning

confidence: 99%

The anti-tumor potential of sinomenine: a narrative review

Zhu,

Gao

2023

Transl Cancer Res

View full text Add to dashboard Cite

show abstract

“…Grape seed proanthocyanidins (GSP) is a general term for a large class of polyphenolic compounds that have antioxidant activity. GSP has various biological activities and has been proven to have good antitumor effects, as well as certain inhibitory effects on cervical cancer (Li et al, 2022a), carcinoma of the urinary bladder (Yang et al, 2021a), lung cancer (Xu et al, 2021a;Mao et al, 2023), colon cancer (Aiello et al, 2019;Zhang et al, 2019), liver cancer (Feng et al, 2019), prostate cancer (Chen and Yu, 2019), among others. In a study on liver cancer cells, GSP was found to trigger ROS production, decrease matrix-metalloproteinases (MMPs), and increase caspase-3 activity in HepG2 cells (Wang et al, 2020), proving that GSPs may induce ROS production and, consequently, lead to MMP reduction and caspase-3 activation.…”

Section: Grape Seedsmentioning

confidence: 99%

Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most common malignant tumor of the central nervous system (CNS). It is a leading cause of death among patients with intracranial malignant tumors. GBM exhibits intra- and inter-tumor heterogeneity, leading to drug resistance and eventual tumor recurrence. Conventional treatments for GBM include maximum surgical resection of glioma tissue, temozolomide administration, and radiotherapy, but these methods do not effectively halt cancer progression. Therefore, development of novel methods for the treatment of GBM and identification of new therapeutic targets are urgently required. In recent years, studies have shown that drugs related to mitophagy and mitochondrial apoptosis pathways can promote the death of glioblastoma cells by inducing mitochondrial damage, impairing adenosine triphosphate (ATP) synthesis, and depleting large amounts of ATP. Some studies have also shown that modern nano-drug delivery technology targeting mitochondria can achieve better drug release and deeper tissue penetration, suggesting that mitochondria could be a new target for intervention and therapy. The combination of drugs targeting mitochondrial apoptosis and autophagy pathways with nanotechnology is a promising novel approach for treating GBM.This article reviews the current status of drug therapy for GBM, drugs targeting mitophagy and mitochondrial apoptosis pathways, the potential of mitochondria as a new target for GBM treatment, the latest developments pertaining to GBM treatment, and promising directions for future research.

show abstract

From mundane to classic: Sinomenine as a multi‐therapeutic agent

Li,

Zhong,

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

Sinomenine (SIN) is an active substance extracted from the traditional Chinese medicine Sinomenium acutum. SIN has been shown to mediate a wide range of pharmacological actions and is known to possess good anti‐inflammatory, immunosuppressive, antitumor, neuroprotective, antiarrhythmic, and other pharmacological effects. Understanding the underlying mechanisms and the association between the targets and the pharmaceutical effects of different diseases is crucial to the discovery and design of new treatment strategies. In this review, we aim to give a systematic and comprehensive overview on the research progress of SIN over the past 20 years. We first describe the metabolic process of SIN in vivo and then summarize the pharmacological activities of SIN on different diseases. The potential binding properties of SIN, as well as the potential of developing new SIN‐based drugs are also reviewed.

show abstract

Sinomenine Inhibits the Progression of Bladder Cancer Cells by Downregulating LncRNA-HEIH Expression

Cited by 4 publications

References 30 publications

The anti-tumor potential of sinomenine: a narrative review

The anti-tumor potential of sinomenine: a narrative review

Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment

From mundane to classic: Sinomenine as a multi‐therapeutic agent

Contact Info

Product

Resources

About